Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth differentiation factor 15 (GDF-15) is superior to that of N-t...

Descripción completa

Detalles Bibliográficos
Autores: Mendez Fernandez, Ana Belen, Ferrero-Gregori, Andreu|||0000-0001-6492-2416, García Osuna, Álvaro|||0000-0002-6682-0226, Mirabet Pérez, Sonia|||0000-0001-5955-2748, Pirla, Maria José, Cinca, Juan|||0000-0003-4819-4265, Ordóñez, J. (Jordi)|||0000-0003-4896-5832, Roig, Eulàlia|||0000-0002-3421-4985
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:238784
Acceso en línea:https://ddd.uab.cat/record/238784
https://dx.doi.org/urn:doi:10.1002/ehf2.12621
Access Level:acceso abierto
Palabra clave:GDF-15
HFmrEF
HFpEF
Chronic heart failure
Biomarkers
Descripción
Sumario:The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth differentiation factor 15 (GDF-15) is superior to that of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with HFmrEF or HFpEF. Heart failure patients with either HFpEF or HFmrEF were included in the study. During their first visit to the HF unit, serum samples were obtained and stored for later assessment of GDF-15 and NT-proBNP concentrations. Patients were followed up by the HF unit. The main endpoint was all-cause mortality. A total of 311 patients, 90 (29%) HFmrEF and 221 (71%) HFpEF, were included. Mean age was 72 ± 13 years, and 136 (44%) were women. No differences were found in GDF-15 or NT-proBNP concentrations between both HF groups. During a median follow-up of 15 months (Q1-Q3: 9-30 months), 98 patients (32%) died, most (71%) of cardiovascular causes. Patients who died had higher median concentrations of GDF-15 (4085 vs. 2270 ng/L, P < 0.0001) and NT-proBNP (1984 vs. 1095 ng/L, P < 0.0001). A Cox multivariable model identified New York Heart Association Functional Class III (P = 0.04), systolic blood pressure (P = 0.01), left atrial diameter (P = 0.03), age.

Similares en LA Referencia